Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MBF-118 in Crohn’s Disease Patients With Stenosis
2022-501464-18-00Phase 2Completed
- Sponsor
- Medibiofarma
- Start
- Nov 2022
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MBF-118 in Crohn's disease, sponsored by Medibiofarma. Primary endpoint: Safety and tolerability of MBF-118 over 28 days. Started Nov 2022; status: completed.
02
Drugs
MBF-118
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2022-501464-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501464-18-00.